B cell stimulatory factor-1/interleukin-4 mRNA is expressed by normal and transformed mast cells

Brown, Melissa A.; Pierce, Jacalyn H.; Watson, Cynthia; Falco, Joseph; Ihle, James N.; Paul, William E.

doi:10.1016/0092-8674(87)90339-4

Cited by 338 publications

(153 citation statements)

References 38 publications

Supporting

Mentioning

142

Contrasting

Unclassified

Order By: Relevance

“…Our positive results in the serum assay for IL-4 may reflect analysis of a larger patient population or an increase in assay sensitivity. Potential sources of IL-4 are T cells (8) and mast cells (9). We speculate that T cells produce at least some of the IL-4 found in scleroderma sera.…”

Section: Discussionmentioning

confidence: 86%

Interleukin‐1, Interleukin‐2, Interleukin‐4, Interleukin‐6, Tumor Necrosis Factor α, and Interferon‐γ Levels in Sera from Patients With Scleroderma

Needleman

Wigley

Stair

1992

Arthritis & Rheumatism

291

147

View full text Add to dashboard Cite

Objective. To determine whether interleukin-la (IL-la), IL-lfl, IL-2, IL-4, interferon-y (IFNy), IL-6, and tumor necrosis factor a (TNFa) are detected more frequently in sera from scleroderma patients than in sera from controls.Methods. Serum concentrations of these cytokines were measured in 78 scleroderma patients and 73 controls, using enzyme-linked immunosorbent assay, radioimmunoassay, and bioassay techniques.Results. IL-2, IL-4, and IL-6 were each detected more frequently in sera from scleroderma patients than in sera from controls. TNFa and IL-la were found with equal frequency in patient and control sera. IL-lP and IFNy were not detected in any sera.Conclusion. IL-2, IL-4, and IL-6 may be among the cytokines that contribute to the disease process in

show abstract

Section: Discussionmentioning

confidence: 86%

Interleukin‐1, Interleukin‐2, Interleukin‐4, Interleukin‐6, Tumor Necrosis Factor α, and Interferon‐γ Levels in Sera from Patients With Scleroderma

Needleman

Wigley

Stair

1992

Arthritis & Rheumatism

291

147

View full text Add to dashboard Cite

show abstract

“…I 1,4 is a cytokine secreted by T cells and mast cells which has pleotropic effects on a wide variety of hematopoietic cell types in vitro (1). Originally described as a growth factor for partially activated B cells (2), IIr4 has subsequently been shown to promote T cell and mast cell growth as well (3)(4)(5), and to have multiple effects on the differentiation of mature lymphocytes (1,(6)(7)(8)(9)(10). These 11,4-mediated effects include increased class II MHC surface expression and IgG1 and IgE production by B cells (6)(7)(8), enhanced generation of T cellmediated cytotoxicity (9), and the induction of surface CD8 expression by CD4+ T cell clones (10) .…”

Section: Resultsmentioning

confidence: 99%

Interleukin 4 expressed in situ selectively alters thymocyte development.

Lewis

Forbush

et al. 1991

The Journal of Experimental Medicine

View full text Add to dashboard Cite

SummaryUsing a transgenic mouse model we show that increased intrathymic expression of interleukin 4 (IL4) significantly perturbs the development of thymocytes. Transgenic double-positive (CD4+CD8+) thymocytes, which are present in dramatically reduced numbers, exhibit increased T cell receptor (TCR) expression and increased mobilization ofcalcium mediated by these receptors. In contrast, transgenic single-positive (CD4+CD8 -and CD4 -CD8+) thymocytes and peripheral T cells exhibit decreased TCRmediated calcium mobilization. The development of CD4 -CD8+ thymocytes is significantly perturbed by 114 expressed in vivo; only peripheral CD4+ T cells are found in significant numbers in transgenic mice, while CD4 -CD8+ thymocytes are present in increased numbers, apparently because of their failure to emigrate to the periphery. In contrast to these selective effects on T cell development, no significant differences in the numbers ofB cells or mast cells, or in the plasma levels of IgE and IgG1 are observed between transgenic and control mice. These observations suggest that 114 in vivo exerts its major effects locally rather than systemically, even when its expression is constitutively increased.

show abstract

“…TNF, initially thought to originate from in situ M , can be produced locally (likely at high levels) by mast cells (34,35). Mast cells are also able to release high amounts of IL-4 (36). Given the fact that GM-CSF can be released by a wide variety of cells, including mast cells and synovial fibroblasts (37,38), all cytokines used in our model may be present at the joint and result in the skewing of newly arriving monocytes into DCs.…”

Section: Discussionmentioning

confidence: 99%

TNF Skews Monocyte Differentiation from Macrophages to Dendritic Cells

Chomarat

Dantin

Bennett

et al. 2003

The Journal of Immunology

170

129

View full text Add to dashboard Cite

Monocytes represent a large pool of circulating precursors of APCs, both macrophages and dendritic cells (DCs). It is thus important to identify the mechanisms by which microenvironment regulates monocyte differentiation. We have previously shown that, upon contact with resting stromal cells such as fibroblasts, monocytes differentiate into macrophages in an IL-6/M-CSF-dependent fashion. Yet, in the inflamed tissue, monocytes need to yield DCs for the adaptive immunity to be induced. Inasmuch as TNF and IL-1 are present at the site of inflammation, we tested their capacity to modulate monocyte differentiation into either macrophages or DCs. TNF, but not IL-1, induce monocytes to become DCs despite the presence of fibroblasts. TNF-induced DCs contain Langerin-positive cells and are able to induce allogenic T cell proliferation. Then, TNF was found to decrease the expression and internalization of the M-CSF receptor, thus overriding the IL-6/M-CSF pathway. Thus, TNF facilitates the induction of adaptive immunity by promoting DC differentiation not only from CD34+ progenitors but also from CD14+ blood precursors.

show abstract

B cell stimulatory factor-1/interleukin-4 mRNA is expressed by normal and transformed mast cells

Cited by 338 publications

References 38 publications

Interleukin‐1, Interleukin‐2, Interleukin‐4, Interleukin‐6, Tumor Necrosis Factor α, and Interferon‐γ Levels in Sera from Patients With Scleroderma

Interleukin‐1, Interleukin‐2, Interleukin‐4, Interleukin‐6, Tumor Necrosis Factor α, and Interferon‐γ Levels in Sera from Patients With Scleroderma

Interleukin 4 expressed in situ selectively alters thymocyte development.

TNF Skews Monocyte Differentiation from Macrophages to Dendritic Cells

Contact Info

Product

Resources

About